InnoHub
Venture Capital Accelerator
USD 60M
Estimated FUM
- Type
- Venture Capital
- HQ
- Guangzhou, Guangdong, China
- Focus
- Technology
About
InnoHub Capital is a venture investor and startup accelerator that backs technology startups and provides incubation, acceleration, education, events, and networking services, with an emphasis on opportunities in China.
Strategies
Venture Capital
Focused strategy
Investment Focus
Sources
Profile sources
- chuang.ba — Technology
Investment Criteria
Investment size
USD 50K - USD 200K
Reported investment size. Actual commitments may vary by stage, ownership and follow-on participation.
Investment Stages
Stages
Seed
Investment Geographies
Primary Markets
China New Zealand
Coverage
Global Regions
Asia Oceania
Coverage is a guide only.
Location
Headquarters
Guangzhou, Guangdong, China
Office Presence
2 countries
China New Zealand
2 known offices
Guangzhou, Guangdong, China (HQ)
Auckland, New Zealand
Similar investors
BOZE Family Office
BOZE Family Office was founded in Beijing in 2009 to manage one family's assets and succession. It invests in public and private markets in China and overseas, including through specialist private funds. BOZE says it manages more than RMB 4 billion in owned assets.
Brill Capital
Brill Capital is a Shanghai family office and private equity investment manager. The firm describes its work as long-term wealth management and asset allocation.
Snowball Effect
New Zealand investment platform providing vetted deal flow and facilitating capital raising for companies and funds. Investors make their own investment decisions; Snowball Effect does not provide investment advice.
Zino Ventures
Zino Ventures invests in New Zealand businesses with the potential to scale into Chinese speaking markets. Zino Ventures has an angel fund that invests in earlier-stage companies, and a newly raised growth fund that looks to invest into high quality NZ companies and help them grow into Chinese speaking markets. Generally our growth investments are $1-2m and into companies that have a product or service that has been validated in NZ and which is a unique proposition in the Chinese speaking markets. Zino will add value to these opportunities by working with management to identify the optimal Asian expansion strategy and then applying our resources, including deep in–market relationships and experience to execute on these strategies. We look at a variety of sectors including market sectors including IT and telecommunications (digital, media, mobile and web), clean tech and renewable energy, biotech, medical devices, food and beverages, financial services, agriculture, AR/VR entertainment, and the Internet of Things.
Impact Enterprise Fund
The Impact Enterprise Fund provides growth capital to businesses who deliver social and/or environmental impact, alongside attractive financial returns. The Impact Enterprise Fund is a collaboration between the ?kina Foundation, New Ground Capital and Impact Ventures. The Impact Enterprise Fund is New Zealand's first domestic focused impact investment fund.
NZGCP
New Zealand Growth Capital Partners (NZGCP), formerly the New Zealand Venture Investment Fund (NZVIF), was established by the New Zealand Government in 2002 to build New Zealand’s early-stage technology investment market. It invests directly in early-stage technology start-ups through the Aspire NZ Seed Fund, and in venture capital funds through the Elevate NZ Venture Fund, a $300m government-funded fund of funds that targets the Series A and B gap.
Other Investors Headquartered in China
#1 Hillhouse Capital Group
Hillhouse is a global investment firm that began investing in public equities, later added a private-equity strategy, and now invests across all stages of company life cycles.
#2 CDH Investments
CDH Investments is a diversified alternative asset manager with private-equity, venture-and-growth, private-credit, public-equity, and real-asset activities; VGC is its venture-and-growth unit.
#6 CoStone Capital
CoStone Capital is a Shenzhen-headquartered Chinese private markets manager. Its strategy spans early venture and private equity, including growth investments and buyouts.
#7 HanKang Capital
Hankang Capital is a venture capital arm of Zhongjianxin Group focused on biomedicine and related healthcare fields, including medical equipment, diagnostics and medical services.
#8 Lilly Asia Ventures
Lilly Asia Ventures is a biomedical venture capital firm that originated in 2008 as an Eli Lilly corporate venture subsidiary and later became an independent investment manager.
#9 Qiming Venture Partners
Qiming Venture Partners is a top-tier VC firm with outstanding reputation. With our exceptional investment performances, we have been widely recognized by investors from around the world.We have a reputation for being entrepreneur friendly.